April 24, 2020 -- AGC Biologics, a contract development and manufacturing organization, and AdaptVac have teamed up to develop a COVID-19 vaccine.
The companies, along with the European Union Horizon 2020-sponsored Prevent-nCoV consortium partners, will use AdaptVac's virus-like particle technology to develop the vaccine. This technology makes ideal scaffolds for displaying vaccine antigens due to their particulate nature and dense repetitive subunit organization, according to the companies.
Clinical trials are expected to begin in late-2020.